Grit­stone's Phase 2 can­cer vac­cine tri­al miss­es the mark, stock spi­rals down

Grit­stone bio’s stock took a tum­ble in pre­mar­ket trad­ing Tues­day morn­ing fol­low­ing mixed da­ta from a Phase 2 study of its can­cer vac­cine, but it’s still mov­ing ahead with a pub­lic of­fer­ing of its stock and Phase 3 plan­ning.

In a late Mon­day re­lease, Grit­stone tout­ed the da­ta as pos­i­tive from the Phase 2 por­tion of its Phase 2/3 GRAN­ITE tri­al of its neoanti­gen can­cer vac­cine in front-line metasta­t­ic mi­crosatel­lite sta­ble col­orec­tal can­cer (MSS-CRC). Pro­gres­sion-free sur­vival fa­vored Grit­stone’s vac­cine in an ear­ly trend, even though the dataset is “im­ma­ture,” the com­pa­ny said in its pre­sen­ta­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER